Navigation Links
Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
Date:9/19/2007

RICHMOND, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 3:00 pm (ET) on Wednesday, September 26, 2007 at the UBS 2007 Global Life Sciences Conference in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also d
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
(Date:4/16/2015)... April 16, 2015 According to ... involving an outside source was ranked first among ... injuries related to lifting, pushing, pulling, holding, carrying, ... direct costs. The David Round Company takes statistics ... to working hard to develop and design equipment ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
(Date:4/16/2015)... April 16, 2015  Scientists from Cleave Biosciences will ... the Horizon," at the American Association for Cancer Research ... on Sunday, April 19, 2015 from 3:15pm to ... of Biology, will present new in vivo and mechanism ... inhibitor of p97, a critical enzyme that controls various ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... ST. LOUIS, Nov. 26 Aldrich, a division of,Sigma-Aldrich ... "materials by application",Materials Science catalog. The catalog features ... Electronics, Metal & Ceramic Science,Nanomaterials, Micro/NanoElectronics and Polymer Science. ... of the latest advances,in these fields. , ...
... 26 Thomas K. Equels, President and Managing,Director of ... board of directors,for Hemispherx BioPharma, Inc. (Amex: ... and clinical development,of new drug entities for the treatment ... Equels, legal practice is devoted to ...
... Covaris Incorporated today,announced that during the summer of 2008, ... and continued another successful year throughout,2008. To accommodate ... and marketing organization as well as implementing a,50% expansion ... The Covaris business was built upon the ...
Cached Biology Technology:Aldrich(R) Releases Materials Science Catalog That Includes Products to Advance Sustainable Energy and Nanotechnology Research 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 3Covaris Installed Instrument Base Reaches 500 Units 2
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Exotic bacteria that do not rely on oxygen may have ... early atmosphere, according to a theory that UChicago researcher Albert ... volcanic crater in Siberia. He has found that bacteria ... a surprising twist that scientists must take into account as ...
... WASHINGTON, April 26, 2011 The American Chemical Society ... " Global Challenges/Chemistry Solutions " podcast series showcasing ... friendly production of a key ingredient used to make ... and accompanying website focus on a new way to ...
... Group announced today that four individuals, representing Chile, Mexico ... in Marine Conservation. The 2011 Pew Marine ... dolphin populations, measure the economic and ecological tradeoffs of ... scientific foundation for the establishment of marine protected areas ...
Cached Biology News:Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3Pew announces 2011 recipients of distinguished marine conservation fellowship 2
Request Info...
384 Cluster Tube Racks...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
... Immunogen: Partially purified chicken ... detects vitamin D receptor (VDR) from ... and fish tissues. This antibody ... glucocorticoid receptors. MA1-710 detects both ...
Biology Products: